Anlotinib Completed Phase 2 Trials for Esophageal Squamous Cell Carcinoma (ESCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02649361Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)